The window for watching and waiting on IVDR has firmly closed. For manufacturers of in vitro diagnostic medical devices, authorised representatives, and distributors operating in the EU, IVDR operational readiness in 2026 is no longer a future milestone – it is a present obligation.
This article looks at what delayed operational setup actually costs, where the pressure points concentrate, and how to address the most critical gaps before they become regulatory incidents.
Why “Transition” Language Is Now Misleading
For years, the IVDR was discussed in terms of transition: legacy devices moving across, timelines shifting, competent authorities taking a measured approach. That framing made sense when phase-in periods were active. Now we’re much closer to the final date.
The regulatory infrastructure is almost here. EUDAMED is soon to be mandatory. In this environment, treating IVDR operational readiness in 2026 as something still being phased in is a misreading of where enforcement actually stands.
Manufacturers that have not checked their devices against transition timelines are carrying risk they may not have fully quantified.
What Delayed Setup Actually Means in Practice
Delayed operational setup is not a single gap – it is usually a cluster of interdependent ones. The most common pattern involves an organisation that completed actor registration, began device registration, and then stalled.
Each delay compounds the one before it. The IVDR transition risks that result are not theoretical – devices without complete and accurate EUDAMED records carry no verified regulatory standing, and in a system where competent authorities conduct checks against the database, that absence is visible.
Reclassification: The Underestimated Risk
One of the defining features of the IVDR is the scale of reclassification it introduced. Many IVDs that sat comfortably in a lower risk category under the old IVD Directive likely have moved into a higher class under IVDR Annex VIII rules, bringing in the mandatory involvement of a Notified Body– a shift many manufacturers underestimated.
The impact is now clear: long assessment timelines are pushing certifications close to, or beyond, key compliance deadlines. Where applications are still in progress for reclassified devices, this represents a real IVDR transition risk.
In addition, requirements for scientific validity, analytical, and clinical performance must be clearly demonstrated and properly documented for EUDAMED.
Manufacturers treating IVDR as a continuation of the IVDD are often facing gaps during technical file review – making early alignment and preparation critical.
EUDAMED Data Integrity
EUDAMED is European database for medical devices and IVDs crucial for traceability and market surveillance – not simply a registration portal. Data that is incomplete, inconsistent, or incorrectly coded creates a gap between what an organisation believes its compliance status to be and what authorities actually see.
QMS Alignment with Ongoing Obligations
A Quality Management System built around initial registration rather than ongoing EUDAMED maintenance is a structural risk. IVDR operational readiness in 2026 requires that internal procedures cover not just device and UDI registration, but also serious incident reporting, field safety corrective action notifications, and supply interruption notifications for critical devices.
Manufacturers that have written these procedures but not embedded them – meaning they exist in documentation but have not been tested or assigned to named owners – are carrying QMS risk that will surface during an audit. ISO 13485 alignment is the operational framework through which IVDR obligations are maintained over time, not optional background.
Post-Market Surveillance Infrastructure
IVDR places substantial weight on post-market surveillance, and the data requirements are more demanding than under the old directives. Performance studies, complaint handling, and trend reporting all need to feed into a functioning PMS system that is genuinely operational – not nominally in place.
For Class C and D devices in particular, the IVDR requires a post-market performance follow-up (PMPF) plan. If that plan exists on paper but has not been operationalised, it creates an exposure that becomes visible during a notified body audit.
IVDR Readiness with Obelis
Obelis supports manufacturers and non-EU organisations navigating IVDR operational readiness across the full range of what that requires.
This includes EUDAMED Registration covering actor and devicemodules, Authorised Representative (EAR) services for non-EU manufacturers, Technical File Review, CE Marking Guidance, and QMS Support aligned with ongoing IVDR obligations.
If you are not certain where your gaps are, that is precisely where the conversation starts. Reach out to Obelis today and let us help you move forward from where you actually are.
FAQs
Reclassification under IVDR Annex VIII moved a large number of devices into categories requiring notified body involvement for the first time. For manufacturers with no prior experience with third-party conformity assessment, the lead times, documentation requirements, and audit preparation involved were genuinely new territory late starters face timeline pressure that compounds quickly.
Yes, in practical terms. Distributors operating in the EU are increasingly asking for verified EUDAMED records as part of onboarding and due diligence. Devices with gaps in registration or certificate linkage create uncertainty that distributors are less willing to absorb as enforcement becomes more active. The commercial exposure from delayed setup extends well beyond the regulatory relationship with competent authorities.
An honest gap assessment against the four key areas – actor registration, device and UDI data, certificate linkage, and QMS alignment – is the right starting point.
Prioritisation depends on where the most consequential gaps are. For manufacturers without clear internal visibility of their status, external support from a specialist with direct EUDAMED and IVDR experience shortens the timeline significantly and this is what Obelis has already helped thousands of clients with.
Leave a Reply